The danger of relying on the APTT and PT in patients on DOAC therapy, a potential patient safety issue
- PMID: 28447415
- DOI: 10.1111/ijlh.12658
The danger of relying on the APTT and PT in patients on DOAC therapy, a potential patient safety issue
Abstract
Prolongation of the activated partial thromboplastin time (APTT) and prothrombin time/international normalized ratio (PT/INR) correlates poorly with plasma concentrations of direct oral anticoagulant agents (DOACS) including direct thrombin and direct Xa inhibitors. It has been repeatedly demonstrated that patients can have normal APTT and PT/INR with a therapeutic plasma concentration of a DOAC. Clinicians can no longer rely on a normal APTT and PT to determine that an anticoagulated patient is safe to undergo an invasive procedure. Laboratory scientists need to play a key and active role in educating clinicians about the limitations of the APTT and PT in patients on DOAC prophylaxis or therapy.
Keywords: activated partial thromboplastin time; direct oral anticoagulants; prothrombin time; risk; safety.
© 2017 John Wiley & Sons Ltd.
Similar articles
-
Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays.Int J Lab Hematol. 2016 Oct;38(5):505-13. doi: 10.1111/ijlh.12528. Epub 2016 Jun 6. Int J Lab Hematol. 2016. PMID: 27265752
-
Standardization of coagulation tests.Southeast Asian J Trop Med Public Health. 1999;30 Suppl 3:79-85. Southeast Asian J Trop Med Public Health. 1999. PMID: 10926265
-
Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time.Thromb Haemost. 2004 Jun;91(6):1137-45. doi: 10.1160/TH03-12-0794. Thromb Haemost. 2004. PMID: 15175800 Clinical Trial.
-
[Laboratory coagulation tests in patients treated by direct oral anticoagulants (DOACs)].Presse Med. 2015 Jul-Aug;44(7-8):772-8. doi: 10.1016/j.lpm.2015.06.004. Epub 2015 Aug 3. Presse Med. 2015. PMID: 26248706 Review. French.
-
Monitoring the new antithrombotic drugs.Semin Thromb Hemost. 2004 Dec;30(6):683-95. doi: 10.1055/s-2004-861511. Semin Thromb Hemost. 2004. PMID: 15630675 Review.
Cited by
-
Infarct Volumes of Patients with Acute Ischemic Stroke Receiving Direct Oral Anticoagulants due to Non-Valvular Atrial Fibrillation.Ann Indian Acad Neurol. 2021 Jan-Feb;24(1):27-31. doi: 10.4103/aian.AIAN_568_20. Epub 2021 Feb 9. Ann Indian Acad Neurol. 2021. PMID: 33911376 Free PMC article.
-
Analytical verification and comparison of chromogenic assays for dabigatran, rivaroxaban and apixaban determination on BCSXP and STA Compact Max analysers.Biochem Med (Zagreb). 2020 Feb 15;30(1):010706. doi: 10.11613/BM.2020.010706. Biochem Med (Zagreb). 2020. PMID: 32063729 Free PMC article.
-
Beyond Routine Monitoring: A Comprehensive Review of Direct Oral Anticoagulants and the Role of Coagulation Profiles in Their Management.Cureus. 2025 Mar 12;17(3):e80469. doi: 10.7759/cureus.80469. eCollection 2025 Mar. Cureus. 2025. PMID: 40225520 Free PMC article. Review.
-
How I treat pediatric venous thromboembolism in the DOAC era.Blood. 2024 Feb 1;143(5):389-403. doi: 10.1182/blood.2022018966. Blood. 2024. PMID: 37390311 Free PMC article.
-
Updates in Anticoagulation Therapy Monitoring.Biomedicines. 2021 Mar 6;9(3):262. doi: 10.3390/biomedicines9030262. Biomedicines. 2021. PMID: 33800804 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical